.JMP
6MO IGS v STEROIDS.jmp (16.84 kB)
.JMP
DATASET.jmp (1.96 MB)
.JMP
WHL Subset of DATASET for model comparison.jmp (558.51 kB)
.JMP
PBMCs Subset of DATASET for model comparison.jmp (575.32 kB)
.JMP
CD14 Subset of DATASET for model comparison.jmp (560.13 kB)
.JMP
CD8 Subset of DATASET for model comparison.jmp (559.88 kB)
.JMP
CD4 Subset of DATASET for model comparison.jmp (556.66 kB)
.JMP
BL IGS Low-High v REMISSION with STEROIDS.jmp (6.04 kB)
.JMP
BL IGS Low-High v REMISSION with HYDROXYCHLOROQUINE.jmp (6.58 kB)
.JMP
BL IGS Low-High v REMISSION.jmp (3.79 kB)
.JMP
DAS280M v BL IGS.jmp (13.71 kB)
.JMP
6MO IGS v HYDROXYCHLOROQUINE.jmp (16.38 kB)
.JMP
DAS286M v BL IGS.jmp (16.1 kB)
1/0
On A Knife Edge: the role of interferon pathways in the adaptive immune response and potential progression to RA pathogenesis.jmp
Data from the RA-MAP TACERA longitudinal study. Analysis carried out in JMP Pro 15 looking for associations between
baseline IGS and baseline DAS28, 6 month DAS28, and patient remission. Additionally, model comparisons for predicting patient remission using ACPA and RF with/without baseline IGS.
Funding
MRC funding supporting the RA-MAP Consortium
History
UoA
- Clinical Medicine
